<DOC>
	<DOC>NCT02270099</DOC>
	<brief_summary>This clinical performance study is being conducted to evaluate the performance of the Aptima Herpes Simplex Viruses 1 &amp; 2 assay for detection of herpes simplex virus (HSV) type 1 (HSV-1) and HSV type 2 (HSV-2) in swab samples prospectively collected from suspected HSV lesions in the male anogenital region, the female anogenital region, the oral cavity and other mucomembranous or mucocutaneous areas of the face (oral/facial), and the skin. Specimens collected using swabs from viral transport medium (VTM)collection kits and Aptima swab collection kits will be evaluated.</brief_summary>
	<brief_title>Evaluation of the HSV 1 &amp; 2 Assay in Specimens From Symptomatic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>The subject has at least 1 active lesion (lesion with exudates and cellular material; eg, vesicle, ulcer) that is suspected to be caused by HSV (as determined by the clinician) The subject and/or legally authorized representative is willing and able to provide consent prior to study participation (a minor will need the documented consent of his/her parent or legal guardian, unless the site has an institutional review boardapproved waiver for parental consent for minors) The subject has only HSV lesions without exudates and cellular material The subject used a topical or oral antiviral medication used to treat HSV within 21 days of enrollment Subject already participated in this study Subject has a history of illness that the principal investigator (PI) or designee considers could interfere with or affect the conduct, results, and/or completion of the study Subject has a history of illness that the PI or designee considers could create an unacceptable risk to the subject if enrolled in the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>